Genetically modified bacteria stably expressing IL-10 and insulin

US12359210B2 · kind B2 · utility

Assignee

• INTREXON ACTOBIOTICS N.V. · BE

Inventors

• Pieter Rottiers · Zevergem, BE
• Lothar Steidler · Lokeren, BE

Key dates

• Filing date: Nov 29, 2022
• Grant date: Jul 15, 2025
• Expiry date: Nov 29, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The current disclosure provides microorganisms, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a T1D-specific antigen (e.g., a proinsulin) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. The disclosure further provides compositions (e.g., pharmaceutical compositions) methods of using the microorganisms and compositions, e.g., for the treatment of type 1 diabetes (T1D), including those with residual beta-cell function, e.g., recent-onset T1D. The microorganism may be administered orally, delivers the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides. The methods of the present disclosure are particularly well suited for subjects possessing residual beta-cell function, e.g., for subjects with recent-onset T1D.